Company
ASX:DXB
Clinical-stage biopharmaceutical company. Its lead candidate DMX-200 (repagermanium, a chemokine receptor CCR2 antagonist given on top of an angiotensin II receptor blocker) is in the Phase 3 ACTION3 trial for focal segmental glomerulosclerosis (FSGS), a rare glomerular disease that causes scarring of the kidney's filtering units and progressive loss of kidney function toward end-stage renal disease. The trial's primary endpoint is reduction in proteinuria, with eGFR decline as a longer-term measure. A second program, DMX-700, targets orphan respiratory and renal indications and is at an earlier stage. The longevity relevance is narrow and indirect: this is rare-disease nephrology, not a geroscience or ageing-biology program. It is relevant to healthspan only insofar as declining kidney filtration is one of the core organ-decline endpoints, and DMX-200 addresses a specific genetic and idiopathic kidney disease rather than age-related renal decline in the general population. No approved products and no revenue from product sales; the company is pre-approval and dependent on trial outcomes and regional licensing partners.
Thesis
Market data
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:DXB |
| Secondary listing | None |
| Market cap | ~A$144M (A$0.241 per share, 17 July 2026; down ~57% over the prior twelve months) |
| Status | Listed and trading |
Get in touch
Offering
No commercial services are recorded for this company yet.
People
variis does not publish portraits of named individuals without a licence to do so.
Recent inflection
28 April 2026: Dimerix announced completion of an external blinded assessment of ACTION3's statistical assumptions, confirming the study remains powered at greater than 90% to detect a treatment effect on the proteinuria primary endpoint. In the same announcement the company and its commercial partners decided NOT to proceed with the interim analysis that would have supported a US Accelerated Approval filing, citing added cost, extended timelines, the need for additional confirmatory endpoints, and a reduced probability of success on final endpoints. The stated rationale was a changed FSGS regulatory landscape, including FDA confirmation that proteinuria is acceptable for traditional (full) approval and a recent FDA approval of another FSGS therapy on proteinuria. Net effect: a cleaner path to traditional approval, but the loss of a nearer-term accelerated-approval catalyst, consistent with the shares trading around 57% below their level a year earlier.
Keep reading
Sources
Every entity profile on variis is sourced. Not investment advice.